Penumbra Q1 revenue $241.4M (+18.4%); raises FY 2023 guidance to $1.04-1.06B

Penumbra Inc

2023-Q1 EPS reported $0.22 revenue$241,398,000

Revenue $241.4M (+18.4% YoY, +19.7% constant currency); vascular $142.8M, neuro $98.5M.
Gross margin 62.6%; operating income $8.0M vs loss of $4.0M YoY.
Non-GAAP operating income $10.4M vs non-GAAP loss of $2.3M YoY.
Raised full-year 2023 revenue guidance: $1.04B to $1.06B (23% to 25% growth).
Vascular growth expected slightly above guidance range; Neuro growth below.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Penumbra Inc reported the first quarter ended March 31, 2023 results: revenue $241.4 million. Guidance raised.

Period: the first quarter ended March 31, 2023
Revenue: $241.4 million
Guidance: raised
Result: reported results

Exact text from the filing

Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023. • Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or 19.7% in constant currency 1 , compared to the first quarter of 2022. First Quarter 2023 Financial Results Total revenue

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Penumbra Inc filing history →

Source: SEC EDGAR

accession 0001321732-23-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.